These combinations will likely improve the survival outlook for patients with multiple myeloma.doi:10.1634/theoncologist.2017-0229VishalBhatnagarNicole JGormleyLolaLuoYuan LiShenRajeshwariSridharaThe oncologistBhatnagar V, Gormley NJ, Luo L et al. FDA approval summary: daratumumab for treatment of multiple...
multiple myelomasubcutaneousIntroduction Intravenous daratumumab has shown unprecedented anti-myeloma activity when used as a single agent or in combination with other myeloma therapies. Recently, a subcutaneous formulation of daratumumab was approved for use in both the United States and European Union ...
规格 1mg 5mg 货号:MB2803大包装询价 描述 其他信息 相关文档 小工具 Daratumumab;达雷木单抗 产品简介: Daratumumab is a recombinant IgG1k monoclonal antibody that binds to CD38 and leads to cell apoptosis. Daratumumab was granted orphan drug designation for the treatment of multiple myeloma, diffuse larg...
Daratumumab: the first anti-CD38 monoclonal antibody for the treatment of multiple myelomaCyrille TouzeauBenjamin HébraudXavier Leleu
1. Johnson & Johnson submits supplemental biologics license application to U.S. FDA seeking approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma. News release. Johnson & Johnson. Janu...
The phase 3 PERSEUS trial enrolled patients between 18 and 70 years of age with newly diagnosed multiple myeloma who were eligible for ASCT. An ECOG performance status of 0 to 2 was required.2 Patients were randomly assigned 1:1 to the D-VRd and VRd arms, where treatment was given in ...
1. Johnson & Johnson submits supplemental biologics license application to U.S. FDA seeking approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma. News release. Johnson & Johnson. Janu...
It has been approved for the treatment of multiple myeloma. It is also being examined in the setting of other hematologic malignancies. As DARA targets PCs, it could potentially be used to treat many other disease processes that are antibody mediated. In fact, several case reports and case ...
[Daratumumab for multiple myeloma]. PMID: 30430991 Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis. PMID: 32970151 Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Mul...
Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab. PMID: 35903924 Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma. PMID: 35580269 Daratumumab for immune thrombotic thrombocytopenic purpura. PMID: 34551...